194 related articles for article (PubMed ID: 36368129)
1. Profiling the immune landscape in mucinous ovarian carcinoma.
Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido Dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ
Gynecol Oncol; 2023 Jan; 168():23-31. PubMed ID: 36368129
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer.
Bartl T; Alberts A; Papadopoulos SC; Wolf A; Muellauer L; Hofstetter G; Grimm C; Cacsire Castillo-Tong D
Int J Gynecol Cancer; 2023 Sep; 33(9):1419-1426. PubMed ID: 37094966
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
[TBL] [Abstract][Full Text] [Related]
7. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
8. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
9. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
10. BLEACH&STAIN 15-marker Multiplexed Imaging in 3,098 Human Carcinomas Reveals Six Major PD-L1-driven Immune Phenotypes with Distinct Spatial Orchestration.
Bady E; Möller K; Mandelkow T; Raedler JB; Yang C; Ebner J; Lurati MCJ; Simon R; Vettorazzi E; Büscheck F; Luebke AM; Dum D; Menz A; Sauter G; Höflmayer D; Weidemann S; Fraune C; Uhlig R; Bernreuther C; Jacobsen F; Clauditz TS; Wilczak W; Burandt E; Steurer S; Minner S; Lennartz M; Blessin NC
Mol Cancer Res; 2023 Jun; 21(6):605-613. PubMed ID: 36976297
[TBL] [Abstract][Full Text] [Related]
11. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
13. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
15. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Rocha P; Rodrigo M; Moliner L; Menendez S; Masfarré L; Navarro N; Del Rey-Vergara R; Galindo-Campos M; Taus Á; Giner M; Sanchez I; Rodríguez-Fuster A; Aguiló R; Chalela R; Sánchez-Font A; Belda J; Curull V; Pijuan L; Casadevall D; Clavé S; Bellosillo B; Perera-Bel J; Comerma L; Arriola E
Lung Cancer; 2023 Jul; 181():107257. PubMed ID: 37263182
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Sue-A-Quan R; Patel PG; Shakfa N; Nyi MN; Afriyie-Asante A; Kang EY; Köbel M; Koti M
Gynecol Oncol; 2021 Aug; 162(2):421-430. PubMed ID: 34088514
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
19. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
20. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]